Ebos GroupASX:EBO +0.30%77 Gross Margin % is 12.91% as of Dec. 2025, which is 13% above its 10-year median of 11.46. GuruFocus rates ASX:EBO with a GF Score™ of 77/100 and a GF Value™ of A$31.49 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 118 Medical Distribution companies, Ebos Group ranks worse than 55.08% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Ebos Group's Gross Profit for the
six
months ended in Dec. 2025 was A$881 Mil. Ebos Group's Revenue for the
six
months ended in Dec. 2025 was A$6,828 Mil. Therefore, Ebos Group's Gross Margin % for the quarter that ended in Dec. 2025 was 12.91%.
The historical rank and industry rank for Ebos Group's Gross Margin % or its related term are showing as below:
ASX:EBO'
s Gross Margin % Range Over the Past 10 Years
Min: 9.62 Med: 11.46 Max: 13.35
Current: 13.1
During the past 13 years, the highestGross Margin % of Ebos Group was 13.35%. The lowest was 9.62%. And the median was 11.46%.
ASX:EBO's Gross Margin % is ranked worse than 55.08% of 118
companies
in the Medical Distribution industry
Industry Median: 14.975
vs ASX:EBO: 13.10
Ebos Group had a gross margin of 12.91% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Ebos Group was 5.00% per year.
Ebos Group (ASX:EBO) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ebos Group had a gross margin of 12.91% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Ebos Group Gross Margin % Related Terms
Ebos Group Gross Margin % Historical Data
* Premium members only.
The historical data trend for Ebos Group's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EBO vs MCK, COR, CAH: Gross Margin % Comparison
For the Medical Distribution subindustry, Ebos Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group Gross Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Ebos Group's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ebos Group (ASX:EBO) has a Gross Margin % of 12.91% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Ebos Group and its competitors. This is 13% above median its historical median of 11.46. Over the past decade, Ebos Group's Gross Margin % has ranged from 9.62 to 13.35. According to the industry distribution chart, Ebos Group ranks #65 out of 118 companies in the Medical Distribution industry, placing it in the top 55.1%.
Is Ebos Group's Gross Margin % too high?
Ebos Group's current Gross Margin % of 12.91% is 13% above median its 10-year median of 11.46. Over the past 10 years, this metric has ranged from a low of 9.62 to a high of 13.35. The Medical Distribution industry median Gross Margin % is 14.98. Ebos Group's value of 12.91% is 13.8% below this industry median. Based on the distribution chart, Ebos Group ranks #65 out of 118 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Ebos Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Gross Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #65 out of 118 companies for Gross Margin %. This places Ebos Group in the lower half of its industry. The industry median Gross Margin % is 14.98. Ebos Group's value of 12.91% is 13.8% below this benchmark. Historically, Ebos Group's own Gross Margin % has ranged from 9.62 to 13.35 over the past decade. While the company's 10-year median is 11.46 vs. the industry median of 14.98, Ebos Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Distribution company?
The median Gross Margin % among Medical Distribution companies is 14.98, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current Gross Margin % of 12.91% is 13.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median Gross Margin % is 14.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current Gross Margin % is 12.91%, which is 13% above median its own 10-year median of 11.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$31.49, compared to a current price of A$16.76 — trading 46.8% below its estimated fair value. The current Gross Margin % is 12.91%, which is 13% above median its 10-year median of 11.46 and 13.8% below the Medical Distribution industry median of 14.98. Ebos Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current Gross Margin % is 12.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (ASX:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of A$16.76 is trading 46.8% below its estimated GF Value™ of A$31.49.
GuruFocus considers Ebos Group to be Significantly Undervalued.
Key valuation signals for ASX:EBO:
Gross Margin %: 12.91% (13% above median its 10-year median of 11.46)
GF Value™: A$31.49 vs. price of A$16.76 (46.8% below fair value)
Industry Position: 13.8% below the Medical Distribution median (#65 of 118)
No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
77GF Score
Get the complete analysis for ASX:EBO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EBO has been successfully added to your 
